Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Macrophage activation via Fc gamma II receptors involves the binding of IgG antibodies to FcγRII (CD32) on macrophages, triggering downstream signaling pathways that modulate immune responses. FcγRIIA (CD32A) activates macrophages through ITAM signaling, promoting phagocytosis and cytokine release, while FcγRIIB (CD32B) inhibits activation through ITIM signaling, preventing excessive inflammation. Genetic polymorphisms in FCGR2 genes can influence disease susceptibility, highlighting the clinical significance of this pathway in autoimmune diseases and infection.
Modulation of macrophage activation through agonism/antagonism of FcγRII isoforms, influencing phagocytosis, cytokine release, and immune complex clearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fc gamma II receptor-mediated macrophage activation.